Doctor of Osteopathy Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

John Santoro

Gastroenterology Egg Harbor Township, NJ Doctor of Osteopathy

NPI 1245308196 CMS profile 237475

3205 Fire Road, Suite 4, Egg Harbor Township, NJ 08234

Open in the dashboard

General payments

$80,493

349 records reported · program years 2019–2021

Research payments

$363

Paid to them · 1 record reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$202,946 paid to institutions, not to them · program years 2019–2023

Through program year 2021, John Santoro of Egg Harbor Township, NJ is reported in the CMS Open Payments database as having received $80,493 across 349 general payments and $363 in research payments paid to them. Separately, studies naming them as principal investigator received $202,946 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 Research $363 1
2020 General $15,980 83
2019 General $64,513 266

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Santoro
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to John Santoro were reported at $0. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year John Santoro Gastroenterology median Middle half National median
2019 $64,513 $417 $126–$1,100 $163
2020 $15,980 $224 $74–$624 $114
2021 $0 $352 $106–$1,054 $132
2022 $0 $448 $129–$1,270 $149
2023 $0 $533 $150–$1,390 $160
2024 $0 $605 $160–$1,606 $164
2025 $0 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AbbVie, Inc. $42,153 81 payments
  2. Gilead Sciences, Inc. $20,922 60 payments
  3. Mallinckrodt Enterprises LLC $9,915 8 payments
  4. Intercept Pharmaceuticals, Inc. $5,132 15 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $485 38 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $424 29 payments
  7. Janssen Biotech, Inc. $243 24 payments
  8. Merck Sharp & Dohme Corporation $221 19 payments
  9. QOL Medical, LLC $219 16 payments
  10. Pfizer Inc. $156 12 payments
  11. Other $625 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $57,230 18 payments
  2. Consulting Fee $9,700 3 payments
  3. Food and Beverage $5,130 295 payments
  4. Travel and Lodging $4,317 29 payments
  5. Honoraria $4,100 2 payments
  6. Education $16 2 payments
Products named General payments · program years 2019–2021
  1. MAVYRET $27,645 41 payments
  2. Epclusa $20,191 32 payments
  3. XIFAXAN $485 38 payments
  4. STELARA $279 25 payments
  5. HUMIRA $269 20 payments
  6. DIFICID $221 19 payments
  7. Sucraid $219 16 payments
  8. Entyvio $188 11 payments
  9. XELJANZ $156 12 payments
  10. ZINPLAVA $142 13 payments
  11. Other $1,301 104 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2021
  1. Eli Lilly and Company $363 1 payment

Records

350 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record